Compounds > gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate
Page last updated: 2024-09-03

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Minimal Disease, Residual

gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with Minimal Disease, Residual in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beek, MA; Gobardhan, PD; Heijns, JB; Klompenhouwer, EG; Luiten, EJ; Rutten, HJ; Tetteroo, E; Voogd, AC1

Other Studies

1 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and Minimal Disease, Residual

ArticleYear
Clinical impact of breast MRI with regard to axillary reverse mapping in clinically node positive breast cancer patients following neo-adjuvant chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:5

    Topics: Adult; Aged; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Female; Heterocyclic Compounds; Humans; Lymph Node Excision; Lymphatic Metastasis; Lymphedema; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Netherlands; Organometallic Compounds; Postoperative Complications; Retrospective Studies; Treatment Outcome

2016